BioMarin Reports Q1 Profit Decline Amid Amicus Acquisition Financing and ROCTAVIAN Withdrawal

summarizeSummary

BioMarin Pharmaceutical Inc. reported a significant decline in Q1 net income and diluted EPS year-over-year, driven by increased operating expenses and interest costs related to its $4.8 billion Amicus Therapeutics acquisition and the withdrawal of ROCTAVIAN.

check_boxKey Events

• Q1 Profitability Decline

  Net income decreased to $105.5 million from $185.7 million year-over-year, with diluted EPS falling to $0.54 from $0.95.

• Increased Operating Expenses

  Cost of sales rose by $43.4 million (including a $31.0 million manufacturing charge), R&D by $20.1 million, and SG&A by $52.2 million.

• Amicus Acquisition Financing Details

  Completed the $4.8 billion Amicus Therapeutics acquisition on April 27, 2026, financed by cash, $850 million in new 2034 notes, and $2.8 billion in new senior secured term loans, increasing total debt to approximately $4.3 billion.

• ROCTAVIAN Withdrawal Impact

  Revenue from ROCTAVIAN decreased significantly due to its voluntary withdrawal from the market, as announced in Q1 2026.

auto_awesomeAnalysis

BioMarin's first-quarter results reveal a substantial decrease in profitability, with net income falling to $105.5 million from $185.7 million year-over-year and diluted EPS dropping to $0.54 from $0.95. This decline is primarily attributed to a $43.4 million increase in cost of sales (including a $31.0 million charge for a manufacturing issue), a $20.1 million rise in R&D expenses, and a $52.2 million increase in SG&A, partly due to Amicus acquisition pre-close costs. Interest expense also surged due to new debt. While total revenues saw a modest increase, driven by strong performance in VOXZOGO and other enzyme therapies, the voluntary withdrawal of ROCTAVIAN from the market further impacted revenue. The company successfully financed the $4.8 billion Amicus acquisition through cash on hand, $850 million in new senior unsecured notes, and $2.8 billion in new senior secured term loans, significantly increasing its total indebtedness to approximately $4.3 billion. This strategic acquisition is expected to diversify the rare disease portfolio, but investors should monitor the integration and the impact of increased leverage on future profitability.